Description

RemeGen Co., Ltd. is a biopharmaceutical firm dedicated to the innovation, advancement, and marketing of biologic therapies. The company targets critical unmet medical requirements in autoimmune, oncological, and ophthalmic diseases within Mainland China and the United States. Its current offerings include Telitacicept (RC18), prescribed for the autoimmune condition systemic lupus erythematosus, and Disitamab Vedotin (RC48), utilized in treating various types of cancer. RemeGen maintains a comprehensive pipeline of product candidates at different development phases. RC18 is progressing through Phase III clinical trials for neuromyelitis optica spectrum disorder and rheumatoid arthritis, and Phase II trials for IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis. RC28 has concluded Phase 1 clinical studies for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. In oncology, RC98, a PD-L1 monoclonal antibody, is undergoing Phase I clinical trials for solid tumors. Additionally, RC88 is in Phase 1 trials for mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, other solid tumors, as well as lung and urothelial cancer, while RC108 is in Phase 1 trials for various solid tumors. Furthermore, several products are in pre-clinical development, including RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198, all designed for diverse solid tumors. Ophthalmic disease treatments under pre-clinical investigation include RC208, RC218, and RC228. Founded in 2008, RemeGen Co., Ltd. is headquartered in Yantai, People's Republic of China.